Table 2.
Lever press behavior did not differ across treatment groups and was not impacted by VNS or α2-AR antagonist infusions.
| Vehicle | α2-AR antag. | Two-way ANOVA | |||||
|---|---|---|---|---|---|---|---|
| Sham | VNS | Sham | VNS | pDrug [FDrug] | pVNS [FVNS] | pinteraction [Finteraction] | |
| Group mean (SEM) | |||||||
| Sessions to criteria | 16.3 (2.1) | 21.2 (5.6) | 21.3 (10.7) | 24.2 (6.7) | 0.557 [0.36] | 0.573 [0.33] | 0.881 [0.02] |
| Pretreatment performance | |||||||
| Trials per session | 95.1 (11.0) | 108.4 (6.2) | 113.1 (10.0) | 95.5 (5.0) | 0.774 [0.08] | 0.809 [0.06] | 0.092 [3.12] |
| Percent correct performance | 88.5 (1.8) | 83.2 (1.2 ) | 83.8 (3.5) | 87.1 (2.5) | 0.867 [0.03] | 0.665 [0.19] | 0.088 [3.21] |
| Lever pressing speed (deg/s) | 137.7 (2.2) | 144.3 (6.2) | 151.9 (7.7) | 150.5 (5.3) | 0.375 [0.82] | 0.816 [0.06] | 0.724 [0.13] |
| Trial duration (ms) | 445.1 (24.6) | 400.3 (21.3) | 475.3 (36.3) | 528.5 (45.5) | 0.244 [1.43] | 0.950 [0.0] | 0.467 [0.55] |
| Treatment performance | |||||||
| Trials per session | 103.7 (8.2) | 101.2 (3.4) | 114.4 (8.4) | 94.7 (6.8) | 0.769 [0.088] | 0.134 [2.427] | 0.239 [1.467] |
| Percent correct performance | 86.6 (1.9) | 83.4 (2.1) | 87.5 (2.3) | 87.4 (2.5) | 0.280 [1.228] | 0.459 [0.570] | 0.499 [0.473] |
| Lever pressing speed (deg/s) | 133.9 (3.4) | 142.9 (6.3) | 149.9 (6.3) | 160.3 (7.0) | 0.168 [2.04] | 0.413 [0.70] | 0.954 [0.0] |
| Trial duration (msec) | 421.9 (18.2) | 421.3 (25.3) | 473.3 (36.7) | 464.8 (46.2) | 0.478 [0.52] | 0.946 [0.0] | 0.952 [0.0] |
| Total stimulations delivered | 905.7 (75.7) | 851.7 (34.4) | 997.3 (72.3) | 832.8 (72.0) | 0.593 [0.294] | 0.118 [2.652] | 0.420 [0.677] |